Fig. 3From: Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysisAssessment of heterogeneity between studies; A GOSH plot analysis; B Drapery plot analysisBack to article page